Article

Anticancer efficacy of KRASG12C inhibitors is potentiated by PAK4 inhibitor KPT9274 in preclinical models of KRASG12C mutant pancreatic and lung cancers

2023-03-27

Abstract excerpt

<h4>ABSTRACT</h4> KRASG12C inhibitors have revolutionized the treatment landscape for cancer patients harboring the G12C mutant isoform of KRAS. With the recent FDA approval of sotorasib and adagrasib, patients now have access to more promising treatment options. However, patients who receive these agents as a monotherapy usually develop drug resistance. Thus, there is a need to develop logical combination strate...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 3ec7dfa4-eced-5ac6-af49-6e49f30850b5
DOI: 10.1101/2023.03.27.534309

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Anticancer efficacy of KRASG12C inhibitors is potentiated by PAK4 inhibitor KPT9274 in preclinical models of KRASG12C mutant pancreatic and lung cancersDOI 10.1101/2023.03.27.534309Read

Simultaneous targeting of KRAS and CDK4 synergistically induces durable growth arrest in pancreatic cancer cells.Semantic proximity Read

KRASG 12C-inhibitor-based combination therapies for pancreatic cancer: insights from drug screening.Semantic proximity Read

Targeting KRAS in pancreatic cancer: Emerging therapeutic strategies.Semantic proximity Read

ADT-1004: a first-in-class, oral pan-RAS inhibitor with robust antitumor activity in preclinical models of pancreatic ductal adenocarcinoma.Semantic proximity Read

KRAS Pathway-based Therapeutic Approaches in Pancreatic Cancer.Semantic proximity Read

Differential Response and Resistance to KRAS-Targeted Therapy.Semantic proximity Read

Recent advances in therapeutic targeting of the KRAS pathway in cancer.Semantic proximity Read

Targeting KRAS in pancreatic cancer: new drugs on the horizon.Semantic proximity Read

SHP2 Inhibition Abrogates Adaptive Resistance to KRAS <sup>G12C</sup> -Inhibition and Remodels the Tumor Microenvironment of <i>KRAS</i> -Mutant TumorsSemantic proximity Read

Targeting KRAS(G12C): From Inhibitory Mechanism to Modulation of Antitumor Effects in Patients.Semantic proximity Read

An allele-agnostic mutant-KRAS inhibitor suppresses tumor maintenance signals and reprograms tumor immunity in pancreatic cancer.Semantic proximity Read

Combinations of RAS pathway inhibitors with targeted agents are active in spheroids of patient-derived cells with oncogenic KRAS variants from multiple cancer typesSemantic proximity Read